Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Hostile Bid for Ventana Passes Federal Antitrust Hurdle

NEW YORK (GenomeWeb News) — The US federal anti-trust waiting period has passed on Roche’s hostile takeover bid for Ventana Medical Systems, Roche said today.
  
The expiration of the Hart-Scott-Rodino waiting period satisfies one condition of Roche’s offer, under which it would buy all of Ventana’s outstanding shares for $75 in cash per share, or $3 billion.
 
Roche said the deal still requires the tender of a majority of Ventana's shares of common stock on a fully diluted basis, Ventana's board taking “all necessary actions to make its shareholder rights plan inapplicable to Roche's offer,” and other customary conditions.
 
Earlier this month, Ventana rejected Roche’s offer, calling it “inadequate in multiple respects.” Roche was undeterred, saying that the offer is “full and fair.”

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.